| Canakinumab. | |
| | |
MedLine Citation:
|
PMID: 20065636 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Canakinumab (ACZ885, Ilaris) is a human anti-IL-1beta monoclonal antibody developed by Novartis. Its mode of action is based on the neutralization of IL-1beta signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009 the drug was approved by the US Food and Drug Administration for the treatment of familial cold auto-inflammatory syndrome and Muckle-Wells syndrome, which are inflammatory diseases related to cryopyrin-associated periodic syndromes. The drug is currently being evaluated for its potential in the treatment of rheumatoid arthritis, systemic-onset juvenile idiopathic arthritis, chronic obstructive pulmonary disease, type 1 and 2 diabetes and ocular diseases. Reports from clinical trials suggest that canakinumab is well-tolerated in most patients, and no serious adverse effects have been reported. The drug provides significant advantages over existing competitive therapies, including bimonthly administration and approved use in children. |
| | |
Authors:
|
Eugen Dhimolea |
Related Documents
:
|
19579026 - Abatacept as an option therapy in difficult to treat psoriatic arthritis. 7492236 - Survival analysis of disease modifying antirheumatic drugs in spanish rheumatoid arthri... 7966056 - Sulfate metabolism is abnormal in patients with rheumatoid arthritis. confirmation by i... 11977526 - Advances in experimental studies on treatment of psoriasis by traditional chinese medic... 21745676 - Refining the estimation of illicit drug consumptions from wastewater analysis: co-analy... 10640576 - Modulated release of triterpenic compounds from a o/w/o multiple emulsion formulated wi... |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-01-15 |
Journal Detail:
|
Title: mAbs Volume: 2 ISSN: 1942-0870 ISO Abbreviation: MAbs Publication Date: 2010 Jan-Feb |
Date Detail:
|
Created Date: 2010-02-26 Completed Date: 2010-06-14 Revised Date: 2011-07-19 |
Medline Journal Info:
|
Nlm Unique ID: 101479829 Medline TA: MAbs Country: United States |
Other Details:
|
Languages: eng Pagination: 3-13 Citation Subset: IM |
Affiliation:
|
Tufts University School of Medicine, Boston, MA, USA. eugen.dhimolea@tufts.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anti-Inflammatory Agents / therapeutic use* Antibodies, Monoclonal / therapeutic use* Autoimmune Diseases / drug therapy*, immunology Clinical Trials as Topic Cryopyrin-Associated Periodic Syndromes / drug therapy*, immunology Drug Approval Humans Immunotherapy* Interleukin-1beta / immunology |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Interleukin-1beta; 0/canakinumab |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Guardians at the gate: Biosimilar and patent reform legislation could fundamentally change the guard...
Next Document: Second International Conference on Accelerating Biopharmaceutical Development: March 9-12, 2009, Cor...